CANNABIDIVAROL
Epilepsy
Jazz PharmaceuticalsSmall moleculePhase 2Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 53/ 100
- Competitive Position
- 73/ 100
Competitive context
77 Active assets in the Epilepsy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Topamax SK Life Science, Inc. | Phase 4 | BBB |
Eslicarbazepine Acetate Bial - Portela C S.A. | Phase 4 | BBB |
LAMOTRIGINE Assiut University | Phase 4 | BBB |
Topamax Université de Sherbrooke | Phase 4 | BBB |
Keppra Beijing Tiantan Hospital | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
CANNABIDIVAROL is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →